Advarra’s announcement of a new risk‑based AI governance framework features Raghu Punnamraju, CTO of Velocity Clinical Research, underscoring Velocity’s role in advancing responsible AI in clinical trials. Velocity is a founding member of the Council for Responsible Use of AI in Clinical Trials, a cross‑industry group convened by Advarra that brings together leaders from biopharma, … Read more
At Velocity Clinical Research Albuquerque, clinical research is being delivered in a way that reflects the community it serves. Led by Dr. Sara Friedman, a Principal Investigator with a background in OB/GYN, the Albuquerque site is a female-led team focused on women’s health and vaccines. Their work sits at the intersection of scientific rigor and … Read more
At Velocity in Annapolis, MD, clinical research is delivered as part of everyday healthcare. Located on the Anne Arundel Medical Center campus, the site is embedded within a broader care environment, allowing patients to access clinical trials in the same place they already receive treatment. Turning Access Into Opportunity The Annapolis site serves a population … Read more
Douglas Logan, MD, recently retired from Velocity, but his presence is as big as ever. Talk to our U.S. PIs about their route into research, or their experience at Velocity, and his name is likely to come up. For Matthew Wenker, MD, that story goes back nearly two decades. When he first stepped into clinical … Read more
For much of her early career, Abbie Youkilis, MD focused on changing healthcare from the outside in. Having begun as a pre-med student at Duke, she pivoted into public policy, earning a master’s degree from Harvard and working in Washington on health policy and aging issues. But over time, she found herself drawn back to … Read more
During this year’s World Vaccine Congress, Velocity Clinical Research will host an exclusive “Dine and Discuss” dinner bringing together a select group of senior leaders from across the vaccine and clinical research ecosystem for an off-the-record conversation with vaccine policy and law expert Richard H. Hughes IV. The event forms part of an ongoing series … Read more
There is a logic to the way William Cromwell, MD speaks about cardiometabolic risk — if this, then that. But you never feel as though it would come at the expense of the person sitting opposite him. Over the past 35 years of specialty practice, research, teaching, and publishing, his emphasis has remained the same. … Read more
By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive and fast-moving environment, diversification is often framed as a necessary growth … Read more
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate data that stands up to increasing regulatory and commercial scrutiny. In that environment, long-standing approaches to site selection, which are often shaped by reputation, relationships, … Read more
Over the course of his career, Matthew Wenker, MD, has moved from hospital wards to Phase I units and, eventually, to leading research across three Velocity sites in Cincinnati. Along the way, he has been Principal Investigator (PI) or sub-investigator on close to 500 studies. What stands out in the way he talks about that … Read more